Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 19/20 | 0.70 |
| ▸ | RARB | P10826 | 17/20 | 0.70 |
| ▸ | RARA | P10276 | 16/20 | 0.70 |
| ▸ | RXRA | P19793 | 13/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.70 |
| ▸ | GMNN | O75496 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | THPO | P40225 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5084239 | 1.00 | RARG (0.70) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7082092 | 0.99 | RARG (0.69) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7085649 | 0.91 | RARG (0.72) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL9007208 | 0.91 | RARG (0.72) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL9007203 | 0.91 | RARG (0.72) | RARGRARBRARARXRAKDM4E | |
| Sumarotene SCHEMBL7062910 | 0.90 | RARG (0.70) | RARGRARBRARARXRAKDM4E | |
| Sumarotene SCHEMBL449752 | 0.90 | RARG (0.70) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL11120779 | 0.89 | RARG (0.70) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7087386 | 0.89 | RARG (0.70) | RARGRARBRARARXRAKDM4E | |
| SCHEMBL7082090 | 0.89 | RARG (0.69) | RARGRARBRARARXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| US-4396553-A | Tetrahydronaphthalene and indane compounds useful as anti-tumor agents | HOFFMANN-LA ROCHE INC. (US) | 1983-08-02 | — | — | US | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20080255244-A1 | Administering a Calmodulin-dependent protein kinase (M kinase II) gamma inhibitor; acute myelogenous leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, small cell lung cancer, non-small cell lung cancer, ovarian cancer | FRED HUTCHINSON CANCER RESEARCH CENTER | 2008-10-16 | — | — | US | disclosed |
| US-20020143062-A1 | Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-10-03 | — | — | US | disclosed |
| US-5587367-A | SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-12-24 | — | — | US | disclosed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | disclosed |
| EP-0058370-B1 | TETRAHYDRONAPHTHALENE AND INDAN COMPOUNDS, THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-12-12 | — | — | EP | disclosed |
| US-4396553-A | Tetrahydronaphthalene and indane compounds useful as anti-tumor agents | HOFFMANN-LA ROCHE INC. (US) | 1983-08-02 | — | — | US | disclosed |
| EP-0058370-A1 | Tetrahydronaphthalene and indan compounds, their production and pharmaceutical preparations | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | RARG 744/4885RARB 987/4885RARA 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.